Valneva reports data from chikungunya vaccine trial in adolescents

Valneva has reported initial safety data from the Phase III VLA1553-321 trial evaluating the vaccine candidate VLA1553 in adolescents with chikungunya.

The pivotal, multicentre, placebo-controlled, randomised, double-blinded, prospective study is carried out in partnership with Instituto Butantan.